Cancer Commons, in partnership with the Musella Foundation For Brain Tumor Research & Information, has a pilot study underway seeking to improve outcomes for current glioblastoma (GBM) patients and identify promising therapies for development. The study will use genomic sequencing and other biomarker testing to recommend individualized treatment regimens and will capture and analyze clinical outcomes to inform treatment for future patients.
- US-based Glioblastoma (GBM) patient of any age currently making a treatment decision at first or second recurrence
- Both patient and physician are willing to consider all options available, including clinical trials and off-label, biomarker-driven therapies
- Patient has access to and is willing to share DICOM images and genomic profiling/next generation sequencing results
What to Expect
Once you fill in the form below, our compassionate navigation team will reach out to you so we can learn more about you and your current needs, and confirm eligibility.
Within 10 days of receiving your health history, DICOMs, and genomic profiling results, we will run a Virtual Tumor Board with neuro-oncology experts from across the country.
Our expert nurse navigators and scientists will then work closely with you to help you navigate the process of determining and beginning the next line of treatment, and follow up at regular intervals to provide additional assistance as needed.
We look forward to working with you.
For help with the consent and registration process or if you have questions, please contact Deb Christensen, MSN, Cancer Commons’ Director of Patient Services at 650-448-7968 or email her at: firstname.lastname@example.org